Erratum: Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma (Journal of Cancer Research and Clinical Oncology (2007) 133, (619-625) DOI: 10.1007/s00432-007-0210-4);Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 9, 2007, Pages 619-625

  Hartmann, M ^a   Fedders, M ^b   Schneider, A ^c   Kath, R ^d   Camara, O ^a   Oelschlager H ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b BG Klinik Duisburg   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Medizinische Klinik II   (Germany)

Author keywords

Cost effectiveness; Doxorubicin; Ovarian cancer; Paclitaxel; Platinum; Topotecan

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL; TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; FEMALE; HUMAN; MATHEMATICAL MODEL; OVARY CANCER; PRIORITY JOURNAL; PROBABILITY;

EID: 34447550092     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0313-y     Document Type: Erratum

References (13)

1. Bennett CL, Golub R, Watrs TM et al (1997) Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest 115:227-223
2. Briggs A, Sculpher M (1998) An introduction to Markov-modelling for economic evaluation. Pharmacoeconomics 13(4):397-409
3. Du Bois A, Nejit JP, Thigpen JT (1999) First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care. Ann Oncol 10(Supl):S35-S41
4. Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312-3322
5. Gordon AN, Granai CO, Rose PG et al (2000) Phase II study of liposomal doxorubicin in platinum and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18(17):3093-3100
6. Guyatt GH, Sackett DL, Cook DJ (1994) Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 271:59-63
7. ICON 3 (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomized trial. Lancet 360:505-514
8. McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6
9. Muggia FM, Braly PS, Brady MF et al (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18(1):106-115
10. Ortega A, Dranitsaris G, Sturgeon J et al (1997) Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 66(3):454-463
11. Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699-708
12. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making13(4):322-338
13. Ten Bokkel Huinink W, Gore M, Carmichael J (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15(6):2183-2193